AIM ImmunoTech (DB:HXB2) - Hisse Senedi Fiyatı, Haberler ve Analizler

HXB2 Stoklara Genel Bakış

Bir immüno-farma şirketi olan AIM ImmunoTech Inc., Amerika Birleşik Devletleri'nde birden fazla kanser türünü, viral hastalıkları ve bağışıklık yetersizliği bozukluklarını tedavi etmek için terapötiklerin araştırılmasına ve geliştirilmesine odaklanmaktadır. Daha fazla detay

HXB2 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Gelirin yılda 74.54% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 0.3% oranında düşmesi öngörülüyor

Geliri 1 milyon ABD dolarından az ( $190K )

1 yıldan az nakit akışı var

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 3 daha fazla risk

AIM ImmunoTech Inc. Rakipler

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€22.6m

Heidelberg Pharma

XTRA:HPHA

€103.9m

2invest

XTRA:2INV

€63.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti AIM ImmunoTech
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.16
52 Haftanın En Yüksek Seviyesi	US$0.56
52 Haftanın En Düşük Seviyesi	US$0.13
Beta	-0.36
11 Aylık Değişim	-19.00%
3 Aylık Değişim	-41.73%
1 Yıllık Değişim	-53.71%
33 Yıllık Değişim	-87.14%
5 Yıllık Değişim	-55.03%
Halka arzdan bu yana değişim	-99.93%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	HXB2	DE Biotechs	DE Pazar
7D	-8.5%	-0.7%	-0.02%
1Y	-53.7%	-17.2%	8.2%

Getiri vs. Endüstri: HXB2 geçen yıl % -17.2 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: HXB2 geçen yıl % 8.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is HXB2's price volatile compared to industry and market?
HXB2 volatility
HXB2 Average Weekly Movement	16.8%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: HXB2 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: HXB2 'nin haftalık oynaklığı ( 17% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1966	27	Thomas Equels	aimimmuno.com

Bir immüno-farma şirketi olan AIM ImmunoTech Inc., Amerika Birleşik Devletleri'nde çeşitli kanser türlerini, viral hastalıkları ve bağışıklık yetersizliği bozukluklarını tedavi etmek için terapötiklerin araştırılmasına ve geliştirilmesine odaklanmaktadır. Şirketin öncü ürün adayı, kronik yorgunluk sendromunun (CFS) tedavisi için makromoleküler ribonükleik asit moleküllerinden oluşan bir ilaç olan Ampligen'dir. Ampligen ayrıca pankreas, renal hücreli karsinom, malign melanom, küçük hücreli dışı akciğer, yumurtalık, meme, kolorektal ve prostat kanserlerinin yanı sıra miyaljik ensefalomiyelit, Hepatit B, HIV, COVID-19 ve COVID sonrası durumların tedavisi için de geliştirilmektedir.

AIM ImmunoTech Inc. Temel Bilgiler Özeti

AIM ImmunoTech'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
HXB2 temel i̇stati̇sti̇kler
Piyasa değeri	€12.85m
Kazançlar(TTM)	-€22.98m
Gelir(TTM)	€182.46k

70.4x

P/S Oranı

-0.6x

F/K Oranı

HXB2 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
HXB2 gelir tablosu (TTM)
Gelir	US$190.00k
Gelir Maliyeti	US$36.00k
Brüt Kâr	US$154.00k
Diğer Giderler	US$24.08m
Kazançlar	-US$23.93m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.38
Brüt Marj	81.05%
Net Kâr Marjı	-12,594.21%
Borç/Özkaynak Oranı	93.8%

HXB2 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

HXB2 Stoklara Genel Bakış

Ödüller

Risk Analizi

AIM ImmunoTech Inc. Rakipler

XTRA:CNW

€6.5m

XTRA:MDG1

€22.6m

XTRA:HPHA

€103.9m

XTRA:2INV

€63.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released: US$0.064 loss per share (vs US$0.16 loss in 3Q 2023)

Kellner Group Urges Immediate Change at AIM Immunotech Inc

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

Recent updates

Third quarter 2024 earnings released: US$0.064 loss per share (vs US$0.16 loss in 3Q 2023)

Kellner Group Urges Immediate Change at AIM Immunotech Inc

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Ted D. Kellner Sends a Notice to AIM ImmunoTech

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

New major risk - Revenue and earnings growth

New major risk - Financial position

Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023)

Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board

AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

New major risk - Financial position

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023)

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$0.60 loss per share (vs US$0.41 loss in FY 2022)

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.13 loss in 3Q 2022)

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2022)

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.12 loss in 2Q 2021)

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data

AIM ImmunoTech Inc. Provides Update on Ampligen Long COVID Development Program